News


  • 14 February 2017

    Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model

    Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model

    Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the publication of preclinical data in the January issue of Neuropharmacology, showing that its positive allosteric modulator of GABAA, ganaxolone ameliorates many of the behavioral abnormalities in a  mouse model of adult Angelman syndrome (AS). Evidence from experimental models suggests that AS may be associated with deficient extrasynaptic GABAA receptor function. AS is a rare neurogenetic disorder characterized by severe developmental delay, motor impairments and epilepsy. 

  • 09 February 2017

    Syndax Appoints Richard P. Shea as Chief Financial Officer

    Syndax Appoints Richard P. Shea as Chief Financial Officer

    Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Richard P. Shea is stepping down from his position on the Syndax Board of Directors and is joining the Company as Chief Financial Officer.

  • 01 February 2017

    Marinus Appoints Michael R. Dougherty to its Board of Directors

    Marinus Appoints Michael R. Dougherty to its Board of Directors

    Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Michael R. Dougherty to its Board of Directors.

  • 31 January 2017

    Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board

    Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board

    Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Lisa M. Coussens, Ph.D., to its Scientific Advisory Board.

  • 30 January 2017

    Infographics: 2016 was a banner year for RMI Partners  and our portfolio companies

    Infographics: 2016 was a banner year for RMI Partners and our portfolio companies

    Infographics: 2016 was another banner year for RMI Partners and our portfolio companies. We look forward to building upon these achievements in 2017

  • 24 January 2017

    Atlas Genetics Raises $35m in Series D Fundraising

    Atlas Genetics Raises $35m in Series D Fundraising

    Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces completion of its Series D financing, raising $35 million from a syndicate including all Series C Investors and one new investor, Wondfo Biotech.

  • 23 January 2017

    Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder

    Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business overview to outline the clinical status of its CNS-selective GABAA modulator, ganaxolone, and an overview of near-term value-creating milestones expected in 2017. 

  • 11 January 2017

    JP Morgan Healthcare Conference in San Francisco, on-line report from our Managing Partner Maxim Gorbachev

    JP Morgan Healthcare Conference in San Francisco, on-line report from our Managing Partner Maxim Gorbachev

    The 35th Annual J.P. Morgan Healthcare Conference which currently takes place in San Francisco is no doubt a must attend event to start the year. The following is a short live view on the interesting information during conference from Maxim Gorbachev, Managing Partner of RMI Partners.

  • 09 January 2017

    Celtaxsys Welcomes New Board Member Abel De La Rosa

    Celtaxsys Welcomes New Board Member Abel De La Rosa

    Celtaxsys, a clinical stage pharmaceutical development company focused on advancing novel anti-inflammatory treatment for rare and orphan diseases, announced today the appointment of Dr. Abel De La Rosa to the company board of directors. 

  • 06 January 2017

    Study from MSK and Epic Sciences Shows Only Nuclear-localized AR-V7 Is Predictive of Therapy Benefit for Patients with Metastatic Prostate Cancer

    Study from MSK and Epic Sciences Shows Only Nuclear-localized AR-V7 Is Predictive of Therapy Benefit for Patients with Metastatic Prostate Cancer

    Investigators from Memorial Sloan Kettering Cancer Center (MSK) and Epic Sciences published findings in European Urology, that only nuclear localization of AR-V7 protein in circulating tumor cells (CTCs) from metastatic castration resistant prostate cancer (mCRPC) patient blood samples is predictive of therapeutic benefit.